NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Fog Pharmaceuticals

Fog Pharmaceuticals

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://parabilismed.com/

Last Round

Private Placement

Jun 12, 2026

Est. Valuation

$2.3B

Total Funding Raised

$812M

Company Overview

Parabilis Medicines is a biopharmaceutical company that develops Helicon™ peptide therapeutics designed to target and neutralize historically undruggable intracellular cancer-causing proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoveryprecision medicinebiotechAI drug discoveryundruggable targetsHelicon therapeuticsin silico drug designphysics-based modelingcell-permeable peptidesHEARTsHelicon-Enabled ARTsalpha-radioligand therapeuticstherapeutic co-developmentsmall molecule alternativescomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fog Pharmaceuticals Comps

Public and private peers based on sector, stage, and business model.

Fog Pharmaceuticals comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Fog Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private PlacementJun 12, 2026
IPO AnnouncedJun 10, 2026
Series FJan 8, 2026
Series EMar 1, 2024
Series DNov 21, 2022
Series C
Mar 1, 2021

Fog Pharmaceuticals Investors

Notable investors and investment history

Fog Pharmaceuticals investors
InvestorRounds
Soleus CapitalSeries F
Deerfield ManagementSeries C, Series A, Seed, Series B, Series D
Evercore ISIIPO
Janus Henderson GroupSeries F
Horizons VenturesSeries B
SymBiosis Capital ManagementSeries E
Boyu CapitalSeed, Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2024

    $145M round led by Nextech Invest.

  • Nov 21, 2022

    $178M round led by Farallon Capital Management and Fidelity.

Fog Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Fog Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Fog Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2015
Last FundingJun 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.